Table 6.
Targets of BET inhibitors and related cancers.
| Name | Targets | Cancer | References |
|---|---|---|---|
| Molibresib | BRD2, BRD3, BRD4 | Hematological malignancies | (287) |
| ARV-771 | |||
| HJB97 | |||
| Birabresib | BRD2, BRD3, BRD4 | Solid tumor | (288) |
| MS436 | BRD4 | ||
| BRD4 D1-IN-2 | BRD4 | ||
| AGB1 | |||
| JQ1 | Prostate cancer, Retinoblastoma, Ovarian cancer |
(276, 289, 290) | |
| I-BET762 | SCLC, Pancreatic ductal adenocarcinoma, Hepatocellular carcinoma |
(283, 291, 292) | |
| I-BET151 | BRD4 | Ovarian cancer, Multiple myeloma, MLL-fusion leukemia, |
(133, 293, 294) |
| CPI-0610 | Multiple myeloma, Ovarian cancer |
(286, 295) | |
| PFI-1 | Prostate cancer | (296) | |
| I-BET726 | Human skin squamous cell carcinoma, Neuroblastoma |
(297, 298) | |
| ABBV-744 | Acute myeloid leukemia, Prostate cancer |
(299, 300) | |